Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.56 |
| ▸ | STING1 | Q86WV6 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | AHCY | P23526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792990 | 1.00 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL16871701 | 1.00 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL17889822 | 1.00 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL17612283 | 0.90 | STING1 (0.45) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL22983991 | 0.89 | STING1 (0.56) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL9964279 | 0.89 | STING1 (0.56) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL6895355 | 0.89 | STING1 (0.56) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL14946346 | 0.89 | STING1 (0.56) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL23813544 | 0.89 | STING1 (0.56) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL16271105 | 0.89 | STING1 (0.56) | PDE4APDE4BPDE4CPDE4DSTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-2891717-B1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO LTD (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-10378011-B2 | Oligonucleotide | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20150376611-A1 | OLIGONUCLEOTIDE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2891717-A1 | OLIGONUCLEOTIDE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2015-07-08 | — | — | EP | disclosed |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | PDE4A 1242/4885PDE4B 1411/4885PDE4C 1752/4885 |
| US-10378011-B2 | Oligonucleotide | HNRNPA3, AGO2, RBM3 | PDE4A 2726/4885PDE4B 3567/4885PDE4C 3391/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | PDE4A 1856/4885PDE4B 2194/4885PDE4C 2367/4885 |
| US-20140256668-A9 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | PDE4A 785/4885PDE4B 640/4885PDE4C 711/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | PDE4A 1856/4885PDE4B 2194/4885PDE4C 2367/4885 |
| US-20130338094-A1 | SUBSTITUTED PYRROLO]2,3-D]PYRIMIDINES | DPYD, CCND3, POLD3 | PDE4A 785/4885PDE4B 640/4885PDE4C 711/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | PDE4A 1856/4885PDE4B 2194/4885PDE4C 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.